FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 107 filers reported holding FIVE PRIME THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $61,029,000 | +7.6% | 1,217,898 | +12.7% | 0.01% | -8.3% |
| Q3 2016 | $56,702,000 | +35.9% | 1,080,243 | +7.1% | 0.01% | +33.3% |
| Q2 2016 | $41,710,000 | +8.7% | 1,008,715 | +6.8% | 0.01% | 0.0% |
| Q1 2016 | $38,372,000 | -0.5% | 944,434 | +1.7% | 0.01% | 0.0% |
| Q4 2015 | $38,548,000 | +168.3% | 928,868 | -0.5% | 0.01% | +125.0% |
| Q3 2015 | $14,369,000 | -35.5% | 933,674 | +4.0% | 0.00% | -20.0% |
| Q2 2015 | $22,294,000 | +10.1% | 897,485 | +1.3% | 0.01% | 0.0% |
| Q1 2015 | $20,251,000 | +2.8% | 886,238 | +21.5% | 0.01% | 0.0% |
| Q4 2014 | $19,696,000 | +306.9% | 729,492 | +76.8% | 0.01% | +400.0% |
| Q3 2014 | $4,840,000 | -26.5% | 412,606 | -2.6% | 0.00% | -50.0% |
| Q2 2014 | $6,584,000 | +74.2% | 423,422 | +120.2% | 0.00% | +100.0% |
| Q1 2014 | $3,780,000 | +50.4% | 192,291 | +28.5% | 0.00% | 0.0% |
| Q4 2013 | $2,513,000 | – | 149,693 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eventide Asset Management | 601,000 | $24,587,000 | 1.39% |
| HealthCor Management, L.P. | 1,010,930 | $41,357,000 | 1.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 86,500 | $3,535,000 | 1.38% |
| PURA VIDA INVESTMENTS, LLC | 75,000 | $3,068,000 | 0.90% |
| BB BIOTECH AG | 777,500 | $31,808,000 | 0.88% |
| AWM Investment Company, Inc. | 100,000 | $4,091,000 | 0.71% |
| Granite Point Capital Management, L.P. | 50,000 | $2,046,000 | 0.43% |
| Rock Springs Capital Management LP | 217,700 | $8,906,000 | 0.41% |
| Crestline Management, LP | 50,919 | $2,083,000 | 0.29% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,432,700 | $99,522,000 | 0.24% |